<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170348</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS0396</org_study_id>
    <secondary_id>R01FD006372</secondary_id>
    <nct_id>NCT04170348</nct_id>
  </id_info>
  <brief_title>Daily Vitamin D for Sickle-cell Respiratory Complications</brief_title>
  <acronym>ViDAS-2</acronym>
  <official_title>Daily Vitamin D for Sickle-cell Respiratory Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary M Brittenham, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to answer the question whether daily oral vitamin D supplementation can&#xD;
      reduce the risk of respiratory or lung complications in children and adolescents with sickle&#xD;
      cell disease. Respiratory problems are the leading causes of sickness and of death in sickle&#xD;
      cell disease. The investigators hypothesize that daily oral vitamin D3, compared to monthly&#xD;
      oral vitamin D, will rapidly increase circulating vitamin D3, and reduce the rate of&#xD;
      respiratory complications by 50% or more within the first year of supplementation in children&#xD;
      and adolescents with sickle cell disease.&#xD;
&#xD;
      This study is funded by the FDA Office of Orphan Products Development (OOPD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-year controlled, double-blind, randomized Phase 2 clinical trial comparing the&#xD;
      efficacy in reducing the rate of respiratory events in sickle-cell disease of daily oral&#xD;
      vitamin D3 (3,333 IU/d) with monthly bolus oral vitamin D3, (100,000 IU/mo) as a control. The&#xD;
      scientific premise of the clinical trial is that circulating concentrations of vitamin D3,&#xD;
      the parent compound, are the principal determinant of the anti-infective and immunomodulatory&#xD;
      effects of supplementation.&#xD;
&#xD;
      Eligible participants will be initially screened to determine their blood vitamin D levels.&#xD;
      Those with 25-hydroxyvitamin D levels between 5 and 60 ng/mL will be assigned by chance to&#xD;
      one of the two arms for 24 months. Participants will be checked every month and will have&#xD;
      periodic blood and urine tests to monitor for any side effects of the study treatments.&#xD;
      Children above 5 y/o who can cooperate and understand the procedure will have lung function&#xD;
      test once a year. Showing that a monthly dose of vitamin D reduces lung infections, asthma&#xD;
      and the acute chest syndrome could help establish this simple, low-cost treatment as a way to&#xD;
      decrease sickness and deaths in children and adolescents with sickle-cell disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Controlled, double-masked, randomized Phase 2 clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking will be performed by the Research Pharmacy; all other research staff and participants will be blinded to allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Respiratory Events</measure>
    <time_frame>Screening up to month 24</time_frame>
    <description>Annual rate of respiratory events will be calculated as the sum of respiratory infection, asthma exacerbation, and acute chest syndrome, as ascertained by use of a validated questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change forced vital capacity (FVC; % predicted) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Forced Expiratory Volume in 1 second (FEV1; % predicted) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity ratio</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Forced Expiratory Volume in 1 second (FEV1; % predicted)/Forced Vital Capacity (FVC) [FEV1/FVC] % predicted from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75) % predicted from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio of Residual Lung Volume (RV) to Total Lung Capacity (TLC)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in per cent of the ratio of Residual Lung Volume (RV) to Total Lung Capacity (RV/TLC) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO; % predicted) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fractional Concentration of Exhaled Nitric Oxide (FENO)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Fractional Concentration of Exhaled Nitric Oxide (FENO) in parts per billion (ppb) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Inspiratory Pressure (MIP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Maximum Inspiratory Pressure (MIP; cm H2O) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Expiratory Pressure (MEP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in Maximum Expiratory Pressure (MEP; cm H2O) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 2 (IL 2) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 2 concentration (IL 2; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 4 (IL 4) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 4 concentration (IL 4; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 5 (IL 5) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 5 concentration (IL 5; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 13 (IL 13) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 13 concentration (IL 13; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interferon gamma (IFN gamma). concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interferon gamma concentration (IFN gamma; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 10 (IL 10) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 10 concentration (Iinterleukin 10; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Transforming Growth Factor beta (TGF beta)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum Transforming Growth Factor beta (TGF beta; pg/mL ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood hemoglobin concentration (Hb)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in blood hemoglobin concentration (Hb; g/dL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood platelet concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in blood platelet concentration (platelets/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-reactive protein (CRP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum C-reactive protein (CRP; mg/L) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 1alpha (IL 1alpha) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 1alpha (IL 1alpha; pg/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin 1beta (IL 1beta) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum interleukin 1beta (IL 1beta; pg/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Necrosis Factor alpha (TNF alpha) concentration</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum Tumor Necrosis Factor alpha (TNF alpha; pg/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-terminal telopeptides of Type I collagen (CTX)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Change in serum C-terminal telopeptides of Type I collagen (CTX; ng/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intact N-terminal propeptide of type I procollagen (P1NP)</measure>
    <time_frame>Baseline up to month 24</time_frame>
    <description>Chang in serum intact N-terminal propeptide of type I procollagen (P1NP; Âµg/L) from baseline.=</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Anemia, Sickle Cell</condition>
  <condition>Anemia, Hemolytic, Congenital</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiration Disorders</condition>
  <condition>Acute Chest Syndrome</condition>
  <condition>Lung Diseases</condition>
  <condition>Asthma</condition>
  <condition>Respiratory Tract Infections</condition>
  <condition>Nutrition Disorders</condition>
  <condition>Deficiency Diseases Vitamin</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Daily oral vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3, 3,333 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monthly bolus oral vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus oral vitamin D3, 100,000 IU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daily oral vitamin D3, 3,333 IU</intervention_name>
    <description>Oral vitamin D3, 3,333 IU, will be administered daily.</description>
    <arm_group_label>Daily oral vitamin D3</arm_group_label>
    <other_name>Cholecalciferol for oral administration</other_name>
    <other_name>10-secocholeta-5,7,10(19)-trien-3B-ol for oral administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bolus oral vitamin D3, 100,000 IU</intervention_name>
    <description>Bolus oral vitamin D3, 100,000 IU, will be administered monthly.</description>
    <arm_group_label>Monthly bolus oral vitamin D3</arm_group_label>
    <other_name>Cholecalciferol for oral administration</other_name>
    <other_name>10-secocholeta-5,7,10(19)-trien-3B-ol for oral administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.</description>
    <arm_group_label>Monthly bolus oral vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of sickle cell disease (Hb SS, Hb SC, Hb S-Beta-thalassemia)&#xD;
&#xD;
          2. Age 3-20 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient unwilling or unable to provide written informed consent (and assent, if&#xD;
             applicable)&#xD;
&#xD;
          2. Patient unable or unwilling to comply with requirements of the clinical trial&#xD;
&#xD;
          3. Participation in another clinical trial&#xD;
&#xD;
          4. Current diagnosis of rickets&#xD;
&#xD;
          5. History of hypercalcemia or diagnosis of any medical condition associated with&#xD;
             hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis,&#xD;
             tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia&#xD;
&#xD;
          6. Current use of corticosteroids, excluding inhaled steroids&#xD;
&#xD;
          7. Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)&#xD;
&#xD;
          8. Therapy with thiazide diuretics or lithium carbonate&#xD;
&#xD;
          9. Known liver or renal disease&#xD;
&#xD;
         10. Patients taking medications for pulmonary complications of sickle cell disease not on&#xD;
             a stable dose of medications, as defined by a change in medications or doses within&#xD;
             the three months prior to study entry&#xD;
&#xD;
         11. Patients on chronic red blood cell transfusion therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary M Brittenham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret T Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary M Brittenham, MD</last_name>
    <phone>212 305 7005</phone>
    <email>gmb31@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret T Lee, MD</last_name>
    <phone>212 305 6290</phone>
    <email>ml653@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret T Lee, MD</last_name>
      <phone>212-305-6290</phone>
      <email>ml653@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Miriam Rosen</last_name>
      <phone>646 317 2070</phone>
      <email>mr3989@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen M Arpadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilene Fennoy, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhezhen Jin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meyer Kattan, MD, CM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Miller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeri Nieves, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://journals.lww.com/jpho-online/Abstract/2018/08000/Response_to_Long_term_Vitamin_D_Therapy_for_Bone.8.aspx</url>
    <description>Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease.</description>
  </link>
  <link>
    <url>https://ashpublications.org/bloodadvances/article/2/9/969/15839/Randomized-phase-2-trial-of-monthly-vitamin-D-to</url>
    <description>Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease</description>
  </link>
  <reference>
    <citation>Lee MT, Kattan M, Fennoy I, Arpadi SM, Miller RL, Cremers S, McMahon DJ, Nieves JW, Brittenham GM. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Adv. 2018 May 8;2(9):969-978. doi: 10.1182/bloodadvances.2017013979.</citation>
    <PMID>29712666</PMID>
  </reference>
  <reference>
    <citation>Williams KM, Lee MT, Licursi M, Brittenham GM, Fennoy I. Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2018 Aug;40(6):458-461. doi: 10.1097/MPH.0000000000001155.</citation>
    <PMID>29668535</PMID>
  </reference>
  <reference>
    <citation>De A, Anekwe CV, Kattan M, Yao Y, Jin Z, Brittenham GM, Lee MT. Validation of a Questionnaire to Identify Respiratory Tract Infections in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2021 Jul 1;43(5):e661-e665. doi: 10.1097/MPH.0000000000002164.</citation>
    <PMID>33885042</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Gary M Brittenham, MD</investigator_full_name>
    <investigator_title>James A. Wolff Professor of Pediatrics and Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Acute Chest Syndrome</keyword>
  <keyword>Respiratory Complication</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Acute Chest Syndrome</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Congenital</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Vitamin A Deficiency</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Trientine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

